The Study
Sex differences in the association between plasma copeptin and incident type 2 diabetes: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study
This study looked at people over time and found that women with higher levels of a certain protein (copeptin) were more likely to get diabetes later. But it didn’t change anyone’s levels or treatment—it just watched what happened. So we can say it’s linked, but we don’t know if the protein actually causes diabetes.
Analysis score
Maximum 72 for a cohort study.
Where the score came from
Scientists found that a protein called copeptin in the blood is linked to a higher chance of getting type 2 diabetes — but only in women, not men.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 559 / 100
Quality score
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Key takeaways
Summary
Based on the study abstract and findings.
- 1The improvement is real but very small — not enough on its own to change how doctors screen for diabetes today.
- 2Women with high copeptin had a 49% higher risk of diabetes over 7.7 years.
- 3Adding copeptin to existing risk models improved predictions slightly — moving 4 out of 1,000 women into the right risk group.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Diabetologia
Year
2012
Authors
A. Abbasi, E. Corpeleijn, E. Meijer, D. Postmus, R. Gansevoort, R. Gans, J. Struck, H. Hillege, R. Stolk, G. Navis, S. Bakker
Related Content
Claims (6)
People with persistently high levels of copeptin in their blood have a higher likelihood of developing type 2 diabetes compared to those with lower levels.
Women with higher levels of copeptin in their blood have a 49% higher chance of developing type 2 diabetes over about 7.7 years, even when accounting for other known risk factors like blood sugar and inflammation markers.
Including a blood marker called copeptin in a standard risk model for type 2 diabetes slightly improves its ability to distinguish which women will develop the disease, beyond what is already predicted by glucose, hs-CRP, and urinary albumin levels.
In men, blood levels of copeptin do not predict whether someone will develop type 2 diabetes, even when accounting for other risk factors like blood sugar, waist size, and inflammation markers.
In women, higher levels of copeptin in the blood are associated with a higher likelihood of developing type 2 diabetes, even when accounting for other known biomarkers like fasting glucose and urinary albumin.
Women with higher levels of copeptin in their blood have a greater risk of developing type 2 diabetes, especially if their blood sugar levels were normal at the start of the study.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.